Analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to announce sales of $14.04 million for the current quarter, according to Zacks. Two analysts have made estimates for Inovio Pharmaceuticals’ earnings, with the highest sales estimate coming in at $20.87 million and the lowest estimate coming in at $7.20 million. Inovio Pharmaceuticals posted sales of $12.54 million during the same quarter last year, which suggests a positive year over year growth rate of 12%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year sales of $14.04 million for the current financial year, with estimates ranging from $41.80 million to $72.61 million. For the next fiscal year, analysts anticipate that the company will post sales of $32.52 million per share, with estimates ranging from $28.80 million to $36.23 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS.

INO has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Maxim Group restated a “buy” rating and set a $12.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. Citigroup Inc. initiated coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price target on the stock. Finally, ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.80.

Hedge funds have recently modified their holdings of the business. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $107,000. PNC Financial Services Group Inc. raised its stake in Inovio Pharmaceuticals by 5.0% during the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,000 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $171,000. Bank of America Corp DE raised its stake in Inovio Pharmaceuticals by 14.6% during the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 3,605 shares during the period. Finally, OxFORD Asset Management LLP purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $194,000. 24.83% of the stock is currently owned by institutional investors.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 6.15 on Monday. The firm has a 50-day moving average of $5.73 and a 200 day moving average of $6.65. The stock’s market cap is $554.90 million. Inovio Pharmaceuticals has a 52 week low of $5.28 and a 52 week high of $9.86.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/25/zacks-brokerages-expect-inovio-pharmaceuticals-inc-ino-will-announce-quarterly-sales-of-14-04-million.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.